Regulatory and scientific updates point to a continued shift toward human-relevant preclinical models. The FDA has supported investigational pathways that rely exclusively on human data in certain organoid-based approaches, reflecting the agency’s broader push for new approach methodologies (NAMs). Reporting highlights an October FDA approval of an IND submission supported solely by human vascularized organoid-based combination studies, rather than traditional animal efficacy proof-of-concept testing. The IND by SillaJen supported clinical trial initiation for a regimen combining a PD-1/immune checkpoint therapy and a dual TTK/PLK inhibitor, with preclinical efficacy derived from the vascularized tumor immune microenvironment model (vTIME). Separately, editorial analysis and conference coverage emphasize the practical integration challenge: NAMs can’t always replace in vivo biology for immune interactions and long-term safety, but they can complement fit-for-purpose animal studies where needed. For biotech developers, the direction signals that organoid platforms and human immune microenvironment models are increasingly being treated as decision-grade evidence—potentially accelerating IND timelines while reducing reliance on animal studies when regulatory conditions permit.